BEDMINSTER, N.J., June 24, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Drs. Ben Machielse has joined the Company as Executive Vice President and Chief Operating Officer, effective immediately. In this newly created position, Drs. Machielse's responsibilities will include manufacturing, regulatory affairs, and quality and supply chain management.
Commenting on today's news, Jerry Wisler, President and Chief Executive Officer of Omthera, noted, "Ben brings to Omthera over 20 years of experience in all aspects of biopharmaceutical manufacturing, quality assurance, quality control and operations, and we are very pleased to welcome him into the key position of Chief Operating Officer. As our pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™ progresses, it is critical that we continue to enhance our manufacturing and operational expertise and the robustness of our global supply chain for the anticipated future commercial launch of Epanova, our novel, Omega-3 free fatty acid product. Ben's deep experience in the biopharmaceutical industry will be invaluable as we navigate the next phase of the Company's development."
During his professional career, Drs. Machielse has been involved with the development and approval of seven biologic drugs. Prior to joining Omthera, he spent 11 years with MedImmune, the last five as Executive Vice President Operations. In that role, he led the worldwide manufacturing of therapeutic antibodies, small molecules and vaccine products – including the development and launch of the first H1N1 vaccine product available in the U.S. He also oversaw quality assurance/quality control, GxP compliance, validation, supply chain, health and safety, and other functional areas. Prior to his tenure with MedImmune, Drs.
|SOURCE Omthera Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved